CSF3 and Decreased total neutrophil count: In the current study, we report that gBRCA1 carriers but not gBRCA2 carriers are at high risk of developing grade 3–4 neutropenia and are more likely to need secondary prophylaxis with G-CSF to complete their neoadjuvant or adjuvant chemotherapy.